samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > innovative facility concepts for biopharmaceutical multipurpose pilot and production plants
PUBLICATIONS
European Biopharmaceutical Review

Innovative Facility Concepts for Biopharmaceutical Multipurpose Pilot and Production Plants

The manufacturing requirements of biologics, raw materials, starting materials, excipients and APIs (secondary metabolite, prokaryat, cell culture, transgenic plants and animals, blood products, vaccines and so on), and the dosage form required (aseptic filling, vials, ampoules, syringes, pulmonary systems, transdermal systems etcetera), strongly influence the design concept for pharmaceutical facilities. The greatest influential factors on the design of such facilities are the purpose of the plant (mono or multipurpose), and the size of the plant (the production of cytokines requires less equipment and equipment that is smaller than bulk or rHSA, for example). The production of clinical trial material also needs a smaller plant than for market supply.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Hermann Allgaier, Managing Director of Operations at LSMW GmbH
Dr Hermann Allgaier is the Managing Director of Operations for LSMW GmbH, a company providing consultancy, design, construction and validation services for the pharmaceutical and biotech industry. His 17 years of experience include upstream and downstream processing, engineering, analytical services and internal compliance. He was Responsible Head and led the worldwide process development of new chemical entities at Boehringer Ingelheim in Germany.

Dr Allgaier has made numerous presentations and has had work published in the
areas of biopharmaceutical development, manufacturing and general compliance. He is a Member of PDA, ISPE and APV, where he heads the biopharmaceutical section. Dr Allgaier studied Biochemistry at the University of Tübingen, where he received the Friedrich Weygand Award for his PhD work in the field of peptide antibiotics.

spacer
Dr Hermann Allgaier
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organisation

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.
More info >>

White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement